Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 4/20 | 0.44 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.44 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 3/20 | 0.41 |
| ▸ | CA9 | Q16790 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | ACHE | P22303 | 3/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | REV1 | Q9UBZ9 | 1/20 | 0.37 |
| ▸ | CCR3 | P51677 | 1/20 | 0.36 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3062677 | 0.92 | ABCB1 (0.46) | ABCB1ABCC1ABCG2CA2CA9 | |
| SCHEMBL3041403 | 0.89 | DHCR7 (0.42) | CA2CA9KMT2AACHE | |
| SCHEMBL3062097 | 0.88 | CA9 (0.51) | CA2CA9KMT2ACA12CA1 | |
| SCHEMBL3046501 | 0.84 | KMT2A (0.41) | KMT2A | |
| SCHEMBL3052193 | 0.81 | SIGMAR1 (0.42) | CA2CA9KMT2AACHE | |
| SCHEMBL3048961 | 0.78 | ABCB1 (0.69) | ABCB1ABCC1ABCG2CA2CA9 | |
| SCHEMBL3052670 | 0.72 | ABCB1 (0.71) | ABCB1ABCC1ABCG2KMT2A | |
| SCHEMBL10383284 | 0.70 | ABCB1 (0.74) | ABCB1ABCC1ABCG2KMT2AREV1 | |
| SCHEMBL3056516 | 0.70 | KDM4E (0.66) | ABCB1ABCC1ABCG2CA2CA9 | |
| SCHEMBL3046471 | 0.68 | CA2 (0.60) | ABCB1ABCC1ABCG2CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2155192-B1 | TETRAHYDROISOQUINOLINES AS TUMOUR GROWTH INHIBITORS | STERIX LTD (GB) | 2016-09-28 | — | — | EP | disclosed |
| US-8394825-B2 | Compound | STERIX LIMITED (GB) | 2013-03-12 | — | — | US | disclosed |
| US-20100222299-A1 | COMPOUND | STERIX LIMITED (GB) | 2010-09-02 | — | — | US | disclosed |
| EP-2155192-A2 | TETRAHYDROISOQUINOLINES AS TUMOUR GROWTH INHIBITORS | Sterix Limited (GB) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008117061-A2 | TETRAHYDROISOQUINOLINES AS TUMOUR GROWTH INHIBITORS | STERIX LIMITED (GB) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222299-A1 | COMPOUND | MKI67, VHL, MYC | ABCB1 754/4885ABCC1 3119/4885ABCG2 2021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.